2025
Use of targeted therapy in patients with advanced non-small cell lung cancer in response to broad genomic profiling.
Wang X, Long J, Rothen J, Huang S, Soulos P, Robinson T, Presley C, Goldberg S, Mamtani R, Ma S, Wang S, Kunst N, Dinan M, Gross C. Use of targeted therapy in patients with advanced non-small cell lung cancer in response to broad genomic profiling. Journal Of Clinical Oncology 2025, 43: 11155-11155. DOI: 10.1200/jco.2025.43.16_suppl.11155.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerNon-small cell lung cancerCell lung cancerTargeted therapyLung cancerTargetable alterationsGenomic profilingUsefulness of targeted therapyUS cancer clinicsFirst-line treatmentCohort of patientsClinico-genomic databaseNCCN GuidelinesIdentified patientsPatient populationFDA approvalTreatment selectionPatientsCancer clinicClinical guidelinesTherapyCancerLimited dataTT useFDA approval statusAdherence to SVS Abdominal Aortic Aneurysm Guidelines Among Patients Detected by AI-Based Algorithm
Wilson E, Yao K, Kostiuk V, Bader J, Loh S, Mojibian H, Fischer U, Ochoa Chaar C, Aboian E. Adherence to SVS Abdominal Aortic Aneurysm Guidelines Among Patients Detected by AI-Based Algorithm. Annals Of Vascular Surgery 2025, 120: 108-114. PMID: 40349830, DOI: 10.1016/j.avsg.2025.05.007.Peer-Reviewed Original ResearchAbdominal aortic aneurysmAdherent patientsSurgical interventionAbdominal aortic aneurysm patientsNon-adherent patientsTertiary care centerFollow-up adherenceFollow-up algorithmSVS guidelinesImaging surveillanceSurgical criteriaAneurysm sizeAortic aneurysmIdentified patientsPati entsSurveillance adherenceVascular providersImaging scansDeceased patientsPatientsPhysician evaluationCare centerPatient outcomesStatistical significanceNo significant age differencesPrevalence and prognostic impact of ST-segment elevation in lead aVR among patients with cardiac arrest
Banna S, Schenck C, Kim N, Ali T, Gilmore E, Greer D, Beekman R, Miller P. Prevalence and prognostic impact of ST-segment elevation in lead aVR among patients with cardiac arrest. European Heart Journal Acute Cardiovascular Care 2025, 14: 232-236. PMID: 39873390, DOI: 10.1093/ehjacc/zuaf018.Peer-Reviewed Original ResearchOut-of-hospital cardiac arrestAssociated with higher in-hospital mortalityHigher in-hospital mortalityST-segment elevationIn-hospital mortalityReturn of spontaneous circulationCardiac arrestShockable rhythmLead aVRPoor neurological outcomeAcute coronary syndromeMultivariate logistic regressionPrognostic impactPost-ROSCPrognostic significanceSpontaneous circulationCA patientsNeurological outcomeCoronary syndromeIdentified patientsMultivariable adjustmentMain diseasePatientsCA survivorsArrest characteristics
2024
Association of Physician Certification and Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion
Vora A, Pereira L, Du C, Tan Z, Huang C, Friedman D, Wang Y, Faridi K, Lakkireddy D, Zimmerman S, Higgins A, Kapadia S, Curtis J, Freeman J. Association of Physician Certification and Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion. JACC Cardiovascular Interventions 2024, 18: 591-602. PMID: 39474982, DOI: 10.1016/j.jcin.2024.10.020.Peer-Reviewed Original ResearchPhysician certificationAppendage occlusionAdverse eventsPercutaneous left atrial appendage occlusionLong-term oral anticoagulationDischarged patientsMultivariate Cox proportional hazards regression analysisRate of procedural complicationsLeft atrial appendage occlusionCox proportional hazards regression analysisProportional hazards regression analysisRisk of adverse eventsHazards regression analysisIn-hospital deathOral anticoagulantsWatchman FLXNo significant differenceLAAO devicesProcedural complicationsStratify patientsIntracardiac echocardiographyAtrial fibrillationEligible patientsIdentified patientsMultivariable adjustmentDocetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study
Patrikidou A, Saieva C, Lee-Ying R, Nuzzo P, Zarif T, McClure H, Davidsohn M, Eid M, Spinelli G, Catalano F, Cremante M, Fotia G, Rossetti S, Valenca L, Vauchier C, Ottanelli C, Andrade L, Gennusa V, Mestre R, Fornarini G, Pignata S, Procopio G, Santini D, Ravi P, Sweeney C, Heng D, De Giorgi U, Fizazi K, Russo A, Francini E, Group S. Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study. Clinical Genitourinary Cancer 2024, 22: 102230. PMID: 39461026, DOI: 10.1016/j.clgc.2024.102230.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerAndrogen receptor signaling inhibitorsCastration-resistant prostate cancerAbiraterone acetateOverall survivalProstate cancerElderly patientsSignaling inhibitorsCohort of consecutive patientsSecond-line therapyStandard first-lineReal-world studySecond-lineConsecutive patientsTreatment toxicityFirst-lineD. CONCLUSIONSPatient comorbiditiesIdentified patientsRetrospective designToxicity outcomesD groupInternational cohortPatientsNo differenceGut microbiome profiles to exclude the diagnosis of hepatic encephalopathy in patients with cirrhosis
Bajaj J, O’Leary J, Jakab S, Fagan A, Sikaroodi M, Gillevet P. Gut microbiome profiles to exclude the diagnosis of hepatic encephalopathy in patients with cirrhosis. Gut Microbes 2024, 16: 2392880. PMID: 39189586, PMCID: PMC11352695, DOI: 10.1080/19490976.2024.2392880.Peer-Reviewed Original ResearchConceptsGut microbiome profilesHepatic encephalopathyGut microbiota testMicrobial speciesMicrobiome profilesTraining cohortValidation cohortHE diagnosisStool microbiotaMulticenter prospective cohortDiagnosis of hepatic encephalopathyMulticenter validation cohortNeuropsychological testsNanopore analysisSemi-quantitative questionnaireGutStandard neuropsychological testsProspective cohortIdentified patientsPatientsGold standardCohortDisease processCognitive complaintsDiagnosisSystemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis.
Adelson K, Cheng L, Huang Y, Niu J, Zhao H, Nortje N, Xiang J, Giordano S, Canavan M. Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis. Journal Of Clinical Oncology 2024, 42: 11092-11092. DOI: 10.1200/jco.2024.42.16_suppl.11092.Peer-Reviewed Original ResearchSystemic anticancer therapyCombined chemo-immunotherapyLiquid tumorsSolid tumorsDay of deathEmergency departmentRates of systemic therapySystemic anti-cancer therapySEER-Medicare databaseAnti-cancer therapyChemo-immunotherapyLT patientsSystemic therapyCI patientsSEER-MedicareST patientsIdentified patientsCost of drugsAssociated with higher costsEnd of lifeAnticancer therapyImmunotherapyChemotherapyPatientsTherapyUncertainty-aware deep-learning model for prediction of supratentorial hematoma expansion from admission non-contrast head computed tomography scan
Tran A, Zeevi T, Haider S, Abou Karam G, Berson E, Tharmaseelan H, Qureshi A, Sanelli P, Werring D, Malhotra A, Petersen N, de Havenon A, Falcone G, Sheth K, Payabvash S. Uncertainty-aware deep-learning model for prediction of supratentorial hematoma expansion from admission non-contrast head computed tomography scan. Npj Digital Medicine 2024, 7: 26. PMID: 38321131, PMCID: PMC10847454, DOI: 10.1038/s41746-024-01007-w.Peer-Reviewed Original ResearchDeep learning modelsHematoma expansionIntracerebral hemorrhageICH expansionComputed tomographyNon-contrast head CTNon-contrast head computed tomographyHigh risk of HEHead computed tomographyHigh-confidence predictionsRisk of HENon-contrast headReceiver operating characteristic areaModifiable risk factorsMonte Carlo dropoutOperating characteristics areaPotential treatment targetHead CTVisual markersIdentified patientsAutomated deep learning modelDataset of patientsRisk factorsHigh riskPatients
2023
Feasibility and Utility of Posttraumatic Stress Disorder Screening Among Postpartum Patients at an Urban Safety-Net Institution
Drake E, Larrea N, Wolverton E, Tibbits B, Lazorwitz A, Schultz C. Feasibility and Utility of Posttraumatic Stress Disorder Screening Among Postpartum Patients at an Urban Safety-Net Institution. Obstetrics And Gynecology 2023, 142: 1455-1458. PMID: 37884025, DOI: 10.1097/aog.0000000000005422.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderSafety-net institutionsPostpartum patientsStress disorderMonths of deliveryDepression screening resultsScreening resultsPositive scoreMost patientsPrimary outcomeRoutine careIdentified patientsPrimary careObstetric practitionersPatientsBehavioral healthCareDisordersScoresPeripartumPrevalenceMonthsMechanical thrombectomy for large vessel occlusion strokes beyond 24 hours
Shaban A, Al Kasab S, Chalhoub R, Bass E, Maier I, Psychogios M, Alawieh A, Wolfe S, Arthur A, Dumont T, Kan P, Kim J, De Leacy R, Osbun J, T. A, Jabbour P, Park M, Crosa R, Mascitelli J, Levitt M, Polifka A, Casagrande W, Yoshimura S, Matouk C, Williamson R, Gory B, Mokin M, Fragata I, Romano D, Chowdhry S, Moss M, Behme D, Limaye K, Spiotta A, Samaniego E. Mechanical thrombectomy for large vessel occlusion strokes beyond 24 hours. Journal Of NeuroInterventional Surgery 2023, 15: jnis-2022-019372. PMID: 36593118, DOI: 10.1136/jnis-2022-019372.Peer-Reviewed Original ResearchConceptsLarge vessel occlusionMechanical thrombectomyVessel occlusionAssociated with good outcomeMatched group of patientsSymptomatic intracerebral hemorrhageGroup of patientsLarge vessel occlusion strokeEfficacy of thrombectomyPrimary outcome measureOdds of mortalityRetrospective reviewIntracerebral hemorrhageGood outcomeIdentified patientsClinical trialsThrombectomyAdjusted analysesStroke thrombectomyMedical managementOcclusion strokePatientsAneurysm RegistryControl groupOutcome measures
2022
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3
Meza L, McDermott D, Escudier B, Hutson T, Porta C, Verzoni E, Atkins M, Kasturi V, Pal S, Rini B. Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3. The Oncologist 2022, 28: e167-e170. PMID: 36576430, PMCID: PMC10020797, DOI: 10.1093/oncolo/oyac255.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaProgression-free survivalRenal cell carcinomaTIVO-3Cell carcinomaResponse rateEvaluate PFSAdvanced renal cell carcinomaTreated with axitinibTreatment of patientsClinical efficacyIdentified patientsSubgroup analysisTivozanibAxitinibPatientsCarcinomaSorafenibTreatmentMonthsSubgroupsTrialsTherapySurvivalDrug
2021
Association of Posttraumatic Epilepsy With 1-Year Outcomes After Traumatic Brain Injury
Burke J, Gugger J, Ding K, Kim JA, Foreman B, Yue JK, Puccio AM, Yuh EL, Sun X, Rabinowitz M, Vassar MJ, Taylor SR, Winkler EA, Deng H, McCrea M, Stein MB, Robertson CS, Levin HS, Dikmen S, Temkin NR, Barber J, Giacino JT, Mukherjee P, Wang KKW, Okonkwo DO, Markowitz AJ, Jain S, Lowenstein D, Manley GT, Diaz-Arrastia R, , Badjatia N, Duhaime AC, Feeser VR, Gaudette E, Gopinath S, Keene CD, Korley FK, Madden C, Merchant R, Schnyer D, Zafonte R. Association of Posttraumatic Epilepsy With 1-Year Outcomes After Traumatic Brain Injury. JAMA Network Open 2021, 4: e2140191. PMID: 34964854, PMCID: PMC8717106, DOI: 10.1001/jamanetworkopen.2021.40191.Peer-Reviewed Original ResearchConceptsTraumatic brain injuryGlasgow Coma Scale scorePosttraumatic epilepsyBrief Symptom Inventory-18Positive screening resultsCohort studyBrain injuryScreening resultsGlasgow Outcome Scale Extended scoreScale scoreInitial Glasgow Coma Scale scoreGlasgow Outcome Scale-ExtendedTraumatic Brain Injury (CENTER-TBI) studyProspective cohort studyLong-term outcomesUS trauma centersNegative screening resultsTBI common data elementsBrain Injury StudyHigher BSI scoresAntiepileptogenic therapiesPrimary outcomeTBI cohortIdentified patientsTrauma center
2019
PD66-05 DEVELOPMENT AND VALIDATION OF A HEMATURIA CANCER RISK SCORE TO IDENTIFY PATIENTS AT RISK OF HARBOURING CANCER
Tan* W, Ahmad A, Feber A, Mostafid H, Cresswell J, Fankhauser C, Waisbrod S, Hermanns T, Sasieni P, Kelly J. PD66-05 DEVELOPMENT AND VALIDATION OF A HEMATURIA CANCER RISK SCORE TO IDENTIFY PATIENTS AT RISK OF HARBOURING CANCER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557467.24162.d4.Peer-Reviewed Original Research
2017
Perioperative Outcomes of Open versus Endovascular Repair for Ruptured Thoracoabdominal Aneurysms
Locham S, Grimm J, Arhuidese I, Nejim B, Obeid T, Black J, Malas M. Perioperative Outcomes of Open versus Endovascular Repair for Ruptured Thoracoabdominal Aneurysms. Annals Of Vascular Surgery 2017, 44: 128-135. PMID: 28501656, DOI: 10.1016/j.avsg.2017.02.015.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic Aneurysm, ThoracicAortic RuptureBlood Vessel Prosthesis ImplantationChi-Square DistributionComorbidityDatabases, FactualEndovascular ProceduresFemaleHumansLogistic ModelsMaleMultivariate AnalysisOdds RatioOperative TimePostoperative ComplicationsRetrospective StudiesRisk FactorsTime FactorsTreatment OutcomeUnited StatesConceptsOpen aneurysm repairEndovascular repairRenal failureAneurysm repairPostoperative outcomesPulmonary injuryNational Surgical Quality Improvement Program databaseRisk of renal failureQuality Improvement Program databaseRuptured thoracoabdominal aortic aneurysmThoracoabdominal aortic aneurysmsHigh-risk patient characteristicsEndovascular aneurysm repairAssociated with higher ratesTAAA repairPulmonary complicationsPerioperative outcomesCardiopulmonary complicationsEndovascular approachAortic aneurysmProgram databaseIdentified patientsContemporary outcomesPatient characteristicsOperative time
2013
Methylene Blue is Associated With Poor Outcomes in Vasoplegic Shock
Weiner M, Lin H, Danforth D, Rao S, Hosseinian L, Fischer G. Methylene Blue is Associated With Poor Outcomes in Vasoplegic Shock. Journal Of Cardiothoracic And Vascular Anesthesia 2013, 27: 1233-1238. PMID: 23972738, DOI: 10.1053/j.jvca.2013.02.026.Peer-Reviewed Original ResearchConceptsAssociated with poor outcomesIn-hospital mortalityCardiac surgeryCardiopulmonary bypassPoor outcomePredictors of in-hospital mortalityFirst-line therapyRates of in-hospital mortalityAssociated with morbidityVasoplegic shockPropensity score matchingRisk-benefit analysisIntraoperative variablesRenal failureAdult patientsDecrease morbidityIdentified patientsVasoplegiaIRB approvalInclusion criteriaPatientsMorbidityScore matchingHyperbilirubinemiaMortalityError and Bias in the Evaluation of Prescription Opioid Misuse: Should the FDA Regulate Clinical Assessment Tools?
Meltzer E, Hall W, Fins J. Error and Bias in the Evaluation of Prescription Opioid Misuse: Should the FDA Regulate Clinical Assessment Tools? Pain Medicine 2013, 14: 982-987. PMID: 23594383, DOI: 10.1111/pme.12099.Peer-Reviewed Original ResearchConceptsFood and Drug AdministrationClinical assessment toolScreening toolAssessment toolOpioid-related aberrant behaviorsAberrant medication-related behaviorsOpioid-related risksChronic opioid therapyPrescription opioid misusePredictive of addictionMedication-related behaviorsOpioid therapyPain medicationStandardized questionnaireOpioid misuseIdentified patientsAt-riskDrug AdministrationDiagnose illnessAddictive disordersPatientsAberrant behaviorScreeningComprehensive planAddiction
2010
Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer
Meredith K, Weber J, Turaga K, Siegel E, McLoughlin J, Hoffe S, Marcovalerio M, Shah N, Kelley S, Karl R. Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer. Annals Of Surgical Oncology 2010, 17: 1159-1167. PMID: 20140529, DOI: 10.1245/s10434-009-0862-1.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Squamous CellChemotherapy, AdjuvantCombined Modality TherapyEsophageal NeoplasmsEsophagectomyFemaleFluorouracilHumansMaleMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalPrognosisRadiotherapy, AdjuvantSurvival RateConceptsDisease-free survivalRate of R0 resectionNeoadjuvant therapyOverall survivalR0 resectionEsophageal cancerPathological responsePatients treated with neoadjuvant therapyComprehensive esophageal cancer databaseEsophageal cancer databaseTreated with NTMedian follow-upResponse to NTKaplan-Meier estimatesDeterminants of survivalMagnitude of benefitOncological outcomesMedian ageCancer DatabaseFisher's exactPathological dataFollow-upIdentified patientsBackgroundEsophageal cancerCancer patients
2008
Response to docetaxel/carboplatin‐based chemotherapy as first‐ and second‐line therapy in patients with metastatic hormone‐refractory prostate cancer
Nakabayashi M, Sartor O, Jacobus S, Regan M, McKearn D, Ross R, Kantoff P, Taplin M, Oh W. Response to docetaxel/carboplatin‐based chemotherapy as first‐ and second‐line therapy in patients with metastatic hormone‐refractory prostate cancer. BJU International 2008, 101: 308-312. PMID: 18184327, DOI: 10.1111/j.1464-410x.2007.07331.x.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate cancerProstate-specific antigenSecond-lineProstate cancerMetastatic hormone-refractory prostate cancerProstate-specific antigen levelGrade 4 toxicityMedian overall survivalPatients treated with DCSecond-line chemotherapyFirst-line chemotherapySecond-line therapyDana-Farber Cancer InstituteCarboplatin AUCOverall survivalChemotherapyDana-FarberIdentified patientsDC groupDocetaxelCarboplatinPatientsCancer InstituteEstramustineRegimens
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply